]MBP87-99 peptide induced strong T cell proliferative responses and IFNgamma cytokine secretion compared with the linear one. Moreover, the interaction of linear and cyclic peptide analogs with the major histocompatibility complex (MHC II, H2-IA s ) and TCR was analyzed using molecular dynamics simulations at the receptor level, in order to gain a better understanding of the molecular recognition mechanisms that underly the different immunological profiles of citrulinated peptides compared to its agonist native counterpart MBP87-99 epitope. The results demonstrate that the citrulination of arginine in combination with the backbone conformation of mutated linear and cyclic analogs are significant elements for the immune response triggering the induction of pro-inflammatory cytokines.
Introduction
Multiple sclerosis (MS) is associated with dysregulation of the immune system, where auto antigens stimulate antibody and CD4 + Th1 cell responses to self antigens, such as, myelin basic protein (MBP), proteolytic protein and myelin oligodendrocyte glycoprotein. 1, 2 This results in pro-inflammatory cytokines (IFN-gamma (γ), TNF-alpha) and demyelination of the myelin sheath. More recently, Th17 cells, secreting IL-17A and IL-17F, have been associated with increased risk of MS. 3 Mutated peptides, altered peptide ligands (APL), are defined as amino acid mutations at T cell receptor (TCR) contact residues of the wild type peptide, which alters immune responses, to antagonists, agonists or superagonists. 4, 5 Methods into altering immune responses in MS, have involved APLs derived from the self autoimmune agonist (wild type) peptide from MBP, residues within 83-99, with the aim to shift pro-inflammatory T helper (Th)1 (IFN-γ) responses to the anti-inflammatory Th2 (IL-4, IL-10) responses. [6] [7] [8] [9] [10] In fact, we have preciously shown, by x-ray crystallography of the MHC-peptide-TCR complex, that modulation of the immune response to a peptide (i.e. changing activity from TCR agonistic to antagonistic or superagonistic) was determined by slight changes in the interaction between the complementarity-determining three loops of the TCR and the altered side chains of the peptide epitope. 4 APL in complex with MHC and/or TCR, from vesicular stomatitis virus and human immunodeficiency virus, only minor conformational changes in the peptide side chains were sufficient enough to lead to profound biological alterations. 11, 12 Likewise, Likewise, APLs derived from the gp10044-59 epitope, associated with melanoma, when bound to HLA-DR4, altered the immune response. This was due to the very subtle, yet crucial changes due to the difference in the mode of epitope side-chain interactions with the TCR. 13 In MS, APLs of the human immunodominant MBP83-99 or the shorter MBP87-99 epitopes have been shown to alter immune responses by diverting Th1 (IFN-γ) to Th2 (IL-10) profile. APLs derived from MBP83-99 epitope were used in phase I human clinical trials with varying responses and side effects. [14] [15] [16] [17] In addition, we previously demonstrated that linear APL of the wild type MBP87-99 with mutations at K 91 , P 96 (TCR contact residues) to R 91 , A 96 ; [R 91 , A 96 ]MBP87-99 protected animals from experimental autoimmune encephalomyelitis (EAE) and it was not able to stimulate the encephalitogenic T cells as it did not interact strongly with TCR. [18] [19] [20] [21] [22] [23] Cyclization of [R 91 , A 96 ]MBP87-99 peptide 7 completely blocked the development of EAE in rats. 22, 24 Using, peripheral blood mononuclear cells from MS patients cultured with linear or cyclic [R 91 , A 96 ]MBP87-99 peptides altered cytokine profile of dominant Th1 cytokines to increased Th2/Th1 cytokine ratio. 25 Protein citrullination is a post-translational modification of peptidyl-arginine, which plays a role in normal functioning of the immune system. 26 However, it has been suspected that citrullination plays a pathophysiological role in a number of conditions, including, psoriasis, chronic obstructive pulmonary disease, multiple sclerosis, inflammatory bowel disease, cancer, rheumatoid arthritis and in degenerative diseases including dementia and Alzheimer's disease. 27 During the citrulination process, the positively charged amino acid Arginine (Arg) is converted into the neutral amino acid Citrulline (Cit) (Scheme 1), which is regulated by peptidylarginine deiminases (PAD). As a result, a non-compact structure is created, leading to degradation by cathepsin D. The post-translational modification of MBP, results in protein unfolding, degradation catalyzed by proteolytic enzymes and subsequently releasing new citrulinated peptide epitopes that could be immunogenic, hence, triggering disease (Schemes 1, 2). [28] [29] [30] In fact, citrulinated proteins of MBP are present in white matter lesions in the central nervous system in MS. 31 In addition, serum (antibodies) from patients with MS react to a citrulinated isomer of MBP (MBP-C8) 32 , as well as being recognized by CD4 + T cells from MS patients. 33 SJL/J mice (H-2 s haplotype; H2-IA s ) is used to induce experimental autoimmune encephalomyelitis (an MS model in mice), as several histopathological, clinical and immunological outcomes mimic those of human MS. 34 In SJL/J mice, residues from the encephalitogenic epitope MBP83-99 bind with high affinity to H2-IA s with the minimum epitope being MBP87-99. 35 28 Herein, we studied the Immunogenicity of the two citrullinated peptides, linear-Cit and cyclic-Cit conjugated to KLH and reduced mannan, in SJL/J mice. We demonstrate that cyclic-Cit-KLH-reduced mannan induced strong T cell proliferative responses and IFN-γ cytokine secretion. In addition, by molecular modeling, linear-Cit and cyclic-Cit were compared to linear native MBP87-99 agonist peptide (linear-native), in order to gain insights in the molecular interactions with H2-IA s and hence the T cell receptor. These results give further evidence that citrulinated MBP peptides may potentially trigger disease in susceptible individuals. 
Results and discussion
Citrullination is an enzymatic conversion of arginine to citrulline on proteins via PAD enzymes. The pathogenisis of MS is still not clear, however, high levels of PAD is present in the white matter of brain suggesting a biochemical pathway in the pathogenisis of MS. 37 Several charged isomers of MBP exist with C1 (most common, most cationic) and C2, C3, C4, C5, C6, C7 and C8 the least cationic are a result of citrullination, deamindation or methylation. In MS patients an increase in MBP citrullination is noted in brain tissue as well as enhanced T cell responsiveness to MBP-C8. 38 Furthermore, in rats, MBP-C8 is immunogenic resulting in T cells that induce experimental autoimmune encephalomyelitis. To further understand the role of citrullination in triggering T cells and cytokines in MS, we determined the immunogenic potential of citrullinated MBP87-99 peptides. Hence, linear-native, linear-Cit and cyclic-Cit peptides were synthesized in-house (Department of Chemistry, University of Patras, Greece) and were > 98 % pure as analyzed by HPLC and Electron Spray Ionization Mass Spectrometry (ESI-MS).
Cyclic-Cit peptide-KLH-reduced mannan, induce strong T cell proliferative responses
SJL/J mice were immunized with linear-Cit and cyclic-Cit peptides, conjugated to keyhole limpet hemocyanin (KLH) and reduced mannan. KLH acts as a linker between peptide and reduced mannan. We have studied in detail the ability of mannan as a carrier to generate immune responses in various model systems. Mannan binds to C-type lectins, including the mannose receptor on antigen presenting cells, 39, 40 and generates immune responses to peptides. Spleen cells were isolated and assessed for T cell stimulation using the T cell proliferation assay. Mice immunized with cyclic-Cit peptide-KLH-reduced mannan, induced strong T cell proliferative responses when restimulated in vitro with cyclic-Cit peptide (red) or linear-Cit (green). Interestingly linear-native peptide did not stimulate T cell responses (blue) which were similar to background non-stimulated T cells (black). Mice immunized with linearCit peptide-KLH-reduced mannan, and, naïve mice, did not induce T cell responses (Fig. 1) . As the T cell epitopes used are CD4 + epitopes it is likely that CD4 + T cells are proliferating. Hence, cyclic-Cit peptide-KLH-reduced mannan induce srong T cell proliferative responses (Table 1 ). 
Cyclic-Cit peptide-KLH-reduced mannan induce strong IFN-γ and IL-4 cytokine responses
The native peptide, MBP87-99, is pathogenic in mice and humans, leading to the induction of Th1 pro-inflammatory cytokines. Mutating 2 TCR contact residues at positions 91, 96, [R 91 ,A 96 ]MBP87-99 (altered peptide ligand, APL), changes the immunogenic profile from Th1 to Th2 with high levels of IL-4 and lower IFN-γ 41 ; citrulination of this linear and cyclic APL stimulates inflammatory Th1 polarization of peripheral blood mononuclear cells from MS patients. 28 Herein, we assessed the immunogenic potential of linear and cyclic-Cit peptides in SJL/J mice. Spleen cells were isolated and assessed for T cell cytokine production (IFN-γ, IL-4, IL-10) using ELISpot assay. Mice immunized with cyclic-Cit peptide-KLH-reduced mannan induced strong IFN-γ and IL-4 cytokine production by T cells after recall with cyclic-Cit peptide (red) or linear-Cit peptide (green), and to a lesser extent after recall with linear-native peptide (blue) ( Fig. 2A, B) ; no IL-10 cytokine secretion was noted (Fig. 2C) . Conversely, mice immunized with linear-Cit peptide-KLH-reduced mannan induced low levels of IL-4 ( Fig. 2B ) but no IFN-γ or IL-10 after all recall peptides; responses were similar to non-immunized naïve mice ( Fig. 2A , C, Table 1 ). This data demonstrates that dominant pro-inflammatory (Th1) cytokine responses are generated following immunization with cyclic-Cit peptide. In MS, proinflammatory cytokine responses are one of the contributing factors to disease progression and demyelination. Thus, as cyclic-Cit peptide induces a strong IFN-γ response it is likely that citrulination may be involved in triggering of disease. To understand the mechanism of citrulinated peptides in disease, further detailed analysis of other cytokines, such as IL-1, IL-8, IL-13, IL-17 need to be measured as well as experimental autoimmune encephalomyelitis experiments following linear or cyclic-Cit peptide immunization need to be conducted. ). Binding pattern A occurs, because of the presence of G86B and K71B in DR2a, compared to V86B and A71B in DR2b. The result is a wider P1 and a shallower P4 pocket in DR2a. 45 In the case of binding pattern B, P4 is much wider, therefore the extended bulky aromatic F 90 side chain has plenty of space and enters P4, resulting in this binding mode. H2-IA s has a similarly structured pocket to DR2b, with the main differences to HLADR2b being G66A, F11B, G13B, T71B and E74B instead of D66A, P11B, R13B, A71B and A74B (Fig. 3A) . In specific, the presence of T71B and V86B results in a wide P4 and shallow P1 respectively. Thus, binding pattern B was considered as the predominant one and therefore docking of the linear-native and linear-Cit peptides within the MHC cleft of H2-IA s homology model, was performed accordingly.
In order to generate the molecular dynamics simulations starting models, the MBP87-99 peptide was docked in the H2-IA s MHC cleft using the peptide binding pattern B from the HLA-DR2b (PDB ID: 1bx2 43 ) crystal structure. Citrulline and alanine residues for [Cit 91 ,A 96 ,Cit 97 ]MBP87-99, were manually mutated in the binding site. In order to explore the different possibilities of the cyclic peptide's docking orientation, it was docked in four different poses, with the coordinates of F 90 and N 92 in pockets P4 and P6 being maintained. All the complexes were energy minimized prior to the MD simulations. The molecular dynamics simulations showed stable binding for the MBP residues 87-95 occupying pockets P1-P9 for linear-Cit, as well as linear-native , which were both stable during the simulations (Fig. 3B) . In both simulations of the linear peptides, residues 96-99 appeared to have fluctuations, despite the high rigidity of the rest of the peptide which is deeper located in the cleft. The cyclic peptides were docked in 4 different orientations to determine the most favorable interacting pose. All initial cyclic peptide conformations had in common the occupancy of F 90 and N 92 in pockets P4 and P6 (Fig. 3C) , in order to evaluate their stability in the MHC cleft. According to the RMSDs of the cyclic peptide (Fig. 3B) , the second simulation (b) was the most stable and could provide a basis for cyclic-Cit peptide recognition by this specific MHC haplotype. Therefore, simulation (b) was used for the analysis regarding cyclic-Cit peptide binding mode. During the simulation, residues F 90 and N 92 , occupy in a consistent manner the main anchor positions P4 and P6. As it can be seen in Fig. 4A , distant pockets P1 and P9 are not occupied due to the cyclic nature of the peptide. However, several other interactions, mainly hydrophobic, may assist the recognition of the cyclic-Cit peptide, such as the aromatic-aromatic interaction between H 88 and H81B, the F 89 side chain aromatic ring with G58A and the hydrophobic interaction between I 93 and Y61B (Fig. 4B) . Side chain electrostatic interactions that were observed during the simulation were H 88 with N82B, Cit 91 with Q70B and Cit 91 with E74B (Fig. 4A) .
Comparison of the binding modes of linear-Cit and cyclic-Cit peptides derived from the molecular dynamics simulations and the crystal structure of MBP85-98, 48 some speculation can be made on their important structural elements for MHC binding. Superimposition of the representative MD conformations of linear-Cit and cyclic-Cit, compared to linear peptide were found in the MBP85-98 -HLA-DR2b crystal structure (Fig.  4B) . 48 MBP85-98 and linear-Cit share many similarities in their positioning in the cleft and the groove anchoring pockets P1, P4, P6 and P9 are similarly occupied by side chain pharmacophore groups of V 87 , F 90 , N 92 and T 95 . F 90 has a side chain rotameric change due to the existence of V 78 B in the H2-IA s complex (Fig. 4A ) compared to Y 78 B in the crystal, which does not allow this kind of rotation. The cyclic-Cit peptide appears to have different occupancies of some residues due to is conformational restrictions. Particularly, side chain of H 88 , which is positioned in between P1 and P2 and side chains V 87 , A 96 , Cit 97 and T 98 which face towards the exposed region (Fig. 4B ). According to our previous work on H2-IA s , 8, 9 residues H 88 , F 89 and K 91 of the linear MBP peptide point up from the MHC groove and could therefore serve as TCR contacts. The effect of mutations at position 91 have been reported not to cause major disruptions to the structures and to the intermolecular interactions between the peptide and the MHC cleft. 8 Based on crystal structures depicting TCR α and β chains, such as the different in terms of TCR binding HLA-DQ1 -MBP84-97 -Hy.1B11 TCR complex 44 , in which the TCR recognition interface is extended towards the MBP residue in position 96 (P 96 ), Cit 97 of our linear-Cit peptide could potentially affect TCR binding and therefore alter response in comparison to the linear-native peptide.
In the case of the cyclic peptide and in our MD simulations, Cit 91 firstly interacts with the backbone of the peptide and more specifically backbone atoms of residues 95, 96 and 97 and secondly with Q70B. Therefore, citrulination at position 91 should be more related to the stability of the cyclic peptide itself, or its affinity to H2-IA s rather than interacting with TCR. On the other hand, residues in cyclic-Cit peptide pointing towards the T cell recognition site according to our structural model are mainly V 87 , A 96 , Cit 97 and T 98 resulting to Cit 97 being totally exposed as a potential TCR contact residue. Cyclization by itself alters the T cell recognition interface of the peptide due to the aforementioned different residues being exposed to make contact with the TCR. Compared to the linear-Cit peptide orientation of, in which citrulline in position 97, is relatively distant to the MHC cleft, in the case of cyclic-Cit, it is well exposed to the TCR interaction interface (Fig. 4B) . This totally different topology of the cyclic-Cit peptide could potentially lead to altered TCR recognition and is likely the reason for altered immune response depicted by increased levels of IFN-γ and IL-4. Moreover, conversion of R 97 to Cit 97 , may differentiate T cell response through its direct interaction with the receptor. 
Conclusion
The immunogenicity of linear-Cit and cyclic-Cit peptides in mice is a first report, which gives insights into the triggers of the disease. (Scheme 3) . 7, 22, 53 The monitoring of the cyclization reaction was carried out using the ninhydrin test, and the reaction mixture was resolved by thin-layer chromatography, nbutanol/acetic acid/water (4/1/1) solvent system and analytical RP-HPLC in C4 Nucleosil RP column with 5μm packing material. The protected cyclic analog was then released from side chain protected groups using 90 % trifluoroacetic acid (TFA) in DCM solution containing 5 % Dithiothreitol/Triethlylsilane/water/Anisole as scavengers. Semi Preparative RP-HPLC for the purification of linear and cyclic peptide analogs was performed using a Nucleosil RP-18 reverse phase column with a 10 μm pack material 4.6x250 mm. The purity of cyclic peptide was estimated to be 98 % according to the analytical RP-HPLC. The identification of synthesized peptides was achieved by Electron Spray Ionization Mass Spectrometry (ESI-MS) ( Figure 5 ). 
Conjugation of Reduced Mannan to linear-Cit and cyclic-Cit Peptide Analogs
The conjugation between peptide to reduced mannan was achieved following a previously described protocol.
1, 7-10, 52, 54 Briefly, 14 mg mannan (poly-mannose from Saccharomyces cerevisiae, Sigma-Aldrich VIC Australia) was dissolved in 1 ml phosphate buffer, pH 6.0, and oxidized with sodium periodate. The oxidized form of mannan was purified using Sephadex G-25 M column pre-equilibrated with bicarbonate buffer pH 9.0. The conjugation of peptide to KLH and then to oxidized mannan was performed in bicarbonate buffer, pH 9.0. The reduced form of mannan was obtained after the addition of sodium borohydride to oxidized mannan-KLH-peptide conjugation. [55] [56] [57] Previously we demonstrated that the conjugation efficacy of peptides or proteins to mannan via SDS-PAGE gels, tricine-PAGE gels and capillary electrophoresis to be 100 % conjugated. [58] [59] [60] 
Mice and Immunizations
Female 6-8 week old SJL/J mice used in all experiments, were purchased from Walter and Eliza Hall Institute (VIC, Australia) and housed at animal facility of AMREP, Burnet Institute, Australia. SJL/J mice were immunized with 50 μg of each peptide-KLH-reduced mannan, twice on days 0 and 14, intradermally (at the base of the tail). All studies were reviewed and approved by Austin Health and Alfred Health Animal Ethics Committee.
Immunological assays

ELISpot assay
Spleen cells from immunized SJL/J mice were isolated 14 days after the last immunization and assessed by ELISpot for IFN-γ, IL-4 and IL-10 secretion by T cells as previously described.
1, 7-10, 52, 54 Spots of activity were detected using a colorimetric AP kit (Biorad, Hercules, CA USA) and counted using an AID ELISpot plate reader (Autoimmun Diagnostika GmbH, Germany). Data are presented as mean spot forming units (SFU) per 1.0 x 10 6 cells.
Proliferation Assay
Spleen cells from immunized SJL/J mice were isolated 25-28 days after the second injection and assessed by [ 3 H]-thymidine uptake of cells. 1 x 10 5 spleen cells in 100 µl of culture media were seeded into 96 well U-bottom plates and incubated for 1-5 days at 37 °C in the presence of recall peptide (10 µg/ml), ConA (internal control) or no peptide (negative control). ConA (internal positive control) yielded proliferation of more than 90,000 cpm and was excluded from the figures and no peptide (cells alone) was used as background negative control. [ 3 H]-thymidine uptake was measured using a β-scintillation counter (Top Count Gamma Counter, Packard, USA).
Homology modeling
The H2-IA u complex, comprising of the MBP1-11 peptide crystal structure (PDB ID: 1k2d; 2.20 Å resolution) 61 was used as a template for the H2-IA s complex homology model as in previous studies. 8, 9 The primary sequence of the two chains were obtained from the Universal Protein Resource (UNIPROT) database (UNIPROT IDs: P14437.1 and P06345.1 respectively). The homology model was built using MODELLER v9.7 62 and the construction involved the disulfide bonds between C107 -C163 in chain A and C15 -C79 and C117 -C173 in chain B. The overall stereochemical quality of the final model was evaluated by the discrete optimized energy (DOPE) 63 and thorough visual inspection.
Docking
The linear peptides were docked in the cleft by means of structural alignment according to the MBP peptide bound to HLA-DR2b (PDB ID: 1bx2 64 ) crystal structure. In the case of linear-Cit residues in positions 91, 96 and 97 were mutated manually. The cyclic-Cit peptide was docked in four different poses. All of them retained F 90 and N 92 in pockets P4 and P6 and were energy minimized using the conjugate gradient algorithm.
Molecular Dynamics (MD)
All MD simulations were performed using the GROMACS software v4.5.5. 65 Following the structural model, a minimization of the receptor topology was performed in order to remove steric clashes between the residues. The minimized topology was then inserted in a pre-equilibrated box containing water and a 0.15 M concentration of Na and Cl ions. The latest AMBER99SB-ILDN 66 force field was used for all the dynamics simulations along with the TIP3P water model. Force field parameters for l-citrulline were generated using the general Amber force field (GAFF) and HF/6-31G*-derived RESP atomic charges. 67 New, manual amino acid entries were added to the forcefield parameters in order to enable cyclization. Each system consisted of the protein, the peptide, ~15,000 water molecules and ~130 ions in an 8x8x8 nm simulation box. The 6 model systems were energy minimized and subsequently subjected to a 10 ns MD equilibration, with positional restraints on protein coordinates. These restraints were released, and 500 ns MD trajectories were produced in constant temperature of 300 K using separate v-rescale thermostats for the protein, the peptide and solvent molecules. A time step of 2 fs was used and all bonds were constrained using the LINCS algorithm. Lennard-Jones interactions were computed using a cut-off of 10 Å, and the electrostatic interactions were treated using PME with the same real-space cutoff.
